Milestone Pharmaceuticals Inc (id:8305 MIST)
1.84 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 2:41:02 PM)
Exchange closed, opens in 1 day 18 hours
About Milestone Pharmaceuticals Inc
Market Capitalization 90.66M
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Headquarters (address) |
1111 Dr. Frederik-Philips Boulevard Montreal H4M 2X6 QC Canada |
| Phone | 514 336 0444 |
| Website | https://www.milestonepharma.com |
| Employees | 47 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MIST |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.12 - 3.52 |
| Market Capitalization | 90.66M |
| P/E trailing | -1.32 |
| P/E forward | -1.98 |
| Price/Sale | 90.66 |
| Price/Book | 4.37 |
| Beta | 1.73 |
| EPS | -1.01 |
| EPS Canada (ID:82, base:722) | 1.84 |